Provided by Tiger Trade Technology Pte. Ltd.

SPYRE THERAPEUTICS INC

90.60
+1.892.13%
Post-market: 90.600.00000.00%19:30 EDT
Volume:886.06K
Turnover:79.81M
Market Cap:7.99B
PE:-45.08
High:91.41
Open:90.00
Low:87.89
Close:88.71
52wk High:110.18
52wk Low:14.51
Shares:88.17M
Float Shares:80.98M
Volume Ratio:0.88
T/O Rate:1.09%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.0100
EPS(LYR):-1.9755
ROE:-22.98%
ROA:-19.81%
PB:8.37
PE(LYR):-45.86

Loading ...

Analysts Offer Insights on Healthcare Companies: Solventum Corporation (SOLV), Argenx Se (ARGX) and Spyre Therapeutics (SYRE)

TIPRANKS
·
Aug 26

Spyre Therapeutics Reports Phase 2 Skyway RA Data for Spy072 Shows Statistically Significant Benefit vs Placebo

Reuters
·
Aug 26

Spyre Therapeutics Shares Down 12.4% Premarket After Co's Experimental Drug Fails to Meet Threshold for Monotherapy Development in Rheumatoid Arthritis

THOMSON REUTERS
·
Aug 26

Spyre Therapeutics Inc : Btig Cuts Target Price to $121 from $132

THOMSON REUTERS
·
Aug 26

Stocks to Watch: Intuit, Spyre Therapeutics, Zoom Communications, nCino

Dow Jones
·
Aug 26

Spyre Therapeutics Stock (SYRE) Tumbles 14% in After-Hours – Here’s What Spooked Investors

TIPRANKS
·
Aug 26

Spyre Therapeutics Won't Prioritize Rheumatoid Arthritis Monotherapy After Trial

Dow Jones
·
Aug 26

Spyre Therapeutics announces results from RA sub-study of SKYWAY basket trial

TIPRANKS
·
Aug 26

Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-Study of the Skyway Phase 2 Trial of Spy072

THOMSON REUTERS
·
Aug 26

Spyre Therapeutics - Spy072 Well Tolerated with Adverse Event Rates Comparable to Placebo

THOMSON REUTERS
·
Aug 26

Spyre Therapeutics Inc: Spy072 in Combination with Il17-a/F in Hidradenitis Suppurativa (Hs) in Late 2027 or Early 2028

THOMSON REUTERS
·
Aug 26

Spyre Therapeutics - Topline Data for Spy072 in Psa and Axspa Expected Q4 2026

THOMSON REUTERS
·
Aug 26

Spyre Therapeutics Inc - Magnitude of Effect Did not Meet Company's Target to Prioritize Monotherapy Development of Spy072 in Rheumatoid Arthritis

THOMSON REUTERS
·
Aug 26

Spyre Therapeutics - Spy072 Shows Statistically Significant Benefits Versus Placebo on Multiple Endpoints

THOMSON REUTERS
·
Aug 26

Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072

GlobeNewswire
·
Aug 26

Is Spyre Therapeutics (SYRE) Fully Priced After Its SPY772 Program And SKYLIGHT Trial Launch?

Simply Wall St.
·
Aug 20

LifeSci Capital Reaffirms Their Buy Rating on Spyre Therapeutics (SYRE)

TIPRANKS
·
Aug 15

Analysts Offer Insights on Healthcare Companies: TransMedics Group (TMDX), Spyre Therapeutics (SYRE) and COMPASS Pathways (CMPS)

TIPRANKS
·
Aug 13

Wedbush Keeps Their Buy Rating on Spyre Therapeutics (SYRE)

TIPRANKS
·
Aug 11

Analysts Offer Insights on Healthcare Companies: Spyre Therapeutics (SYRE), Stereotaxis (STXS) and Tvardi Therapeutics (TVRD)

TIPRANKS
·
Aug 11